Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Gains from Sales and Divestitures: 2021-2024

Historic Gains from Sales and Divestitures for Journey Medical (DERM) over the last 4 years, with Dec 2024 value amounting to $1.1 million.

  • Journey Medical's Gains from Sales and Divestitures rose 3.75% to $927,446 in Q3 2025 from the same period last year, while for Sep 2025 it was $927,446, marking a year-over-year increase of 3.75%. This contributed to the annual value of $1.1 million for FY2024, which is 45.53% up from last year.
  • According to the latest figures from FY2024, Journey Medical's Gains from Sales and Divestitures is $1.1 million, which was up 45.53% from $727,249 recorded in FY2023.
  • Journey Medical's Gains from Sales and Divestitures' 5-year high stood at $1.1 million during FY2024, with a 5-year trough of $136,500 in FY2021.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $727,249 (2023), whereas its average is $693,110.
  • Data for Journey Medical's Gains from Sales and Divestitures shows a peak YoY surged of 147.61% (in 2023) over the last 5 years.
  • Yearly analysis of 4 years shows Journey Medical's Gains from Sales and Divestitures stood at $136,500 in 2021, then spiked by 115.17% to $293,707 in 2022, then skyrocketed by 147.61% to $727,249 in 2023, then soared by 45.53% to $1.1 million in 2024.